Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $39.76, but opened at $47.67. Korro Bio shares last traded at $69.50, with a volume of 255,006 shares traded.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on KRRO shares. Royal Bank of Canada reissued an "outperform" rating and set a $95.00 target price on shares of Korro Bio in a research note on Thursday, September 19th. William Blair started coverage on shares of Korro Bio in a research note on Wednesday, August 14th. They set an "outperform" rating and a $180.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of Korro Bio in a research note on Tuesday, September 17th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $135.00.
Get Our Latest Research Report on Korro Bio
Korro Bio Stock Up 93.7 %
The stock's 50 day moving average is $39.62 and its two-hundred day moving average is $47.43.
Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing analysts' consensus estimates of ($2.39) by ($0.04). As a group, equities analysts anticipate that Korro Bio, Inc. will post -10.09 earnings per share for the current fiscal year.
Institutional Trading of Korro Bio
A number of hedge funds have recently bought and sold shares of KRRO. Brown Brothers Harriman & Co. acquired a new stake in Korro Bio in the 2nd quarter valued at about $28,000. Lynx1 Capital Management LP acquired a new stake in Korro Bio in the 2nd quarter valued at about $129,000. Rhumbline Advisers acquired a new stake in Korro Bio in the 2nd quarter valued at about $279,000. Bank of New York Mellon Corp acquired a new stake in Korro Bio in the 2nd quarter valued at about $649,000. Finally, Tri Locum Partners LP acquired a new stake in Korro Bio in the 2nd quarter valued at about $2,419,000. Institutional investors and hedge funds own 13.18% of the company's stock.
Korro Bio Company Profile
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Further Reading
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
